---
title: "Evotec SE (EVO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EVO.US.md"
symbol: "EVO.US"
name: "Evotec SE"
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T12:37:49.810Z"
locales:
  - [en](https://longbridge.com/en/quote/EVO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EVO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EVO.US.md)
---

# Evotec SE (EVO.US)

## Company Overview

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.evotec.com](https://www.evotec.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.66)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.53% |  |
| Net Profit YoY | -1.61% |  |
| P/B Ratio | 1.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 987481492.60 |  |
| Revenue | 870275831.83 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -24.06% | E |
| Profit Margin | -26.02% | E |
| Gross Margin | -1.00% | E |
| Revenue YoY | 2.53% | C |
| Net Profit YoY | -1.61% | C |
| Total Assets YoY | -10.74% | E |
| Net Assets YoY | -18.80% | E |
| Cash Flow Margin | -9.65% | D |
| OCF YoY | 2.53% | C |
| Turnover | 0.42 | C |
| Gearing Ratio | 57.34% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Evotec SE",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.53%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.61%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "987481492.60",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "870275831.83",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-24.06%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-26.02%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "2.53%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.61%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.74%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.80%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-9.65%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2.53%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "57.34%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.36 | 38/59 | - | - | - |
| PB | 1.23 | 15/59 | 1.44 | 1.31 | 1.16 |
| PS (TTM) | 1.13 | 9/59 | 1.66 | 1.47 | 1.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Overweight | 1 | 25% |
| Underweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.78 |
| Highest Target | 7.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EVO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EVO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EVO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EVO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**